SCHEDULE: Vanguard Group Reports Zero Altimmune Stake After Internal Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Altimmune Inc. common stock following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to Schedule 13G regarding its holdings in Altimmune Inc. Common Stock (CUSIP: 02155H200).
• As of March 13, 2026, The Vanguard Group reports 0 shares beneficially owned, representing 0% of the class.
• This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. itself no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It indicates a change in reporting structure for The Vanguard Group, not a positive or negative assessment of Altimmune Inc.'s prospects or a change in investment decision.

Positives

• The filing is administrative, clarifying The Vanguard Group's reporting structure rather than indicating a divestment based on Altimmune Inc.'s performance or prospects.

Negatives

• No direct negatives related to Altimmune Inc.'s operational or financial performance are indicated in this administrative filing.

Future Outlook

This administrative filing does not contain any forward-looking statements or guidance regarding Altimmune Inc.'s future performance or The Vanguard Group's investment strategy for the company.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that this filing reflects an internal organizational change within The Vanguard Group, a major investment adviser, rather than a change in investment thesis regarding Altimmune Inc. This type of administrative realignment is common among large institutional investors to optimize reporting structures and comply with regulatory guidance.

Stakeholder Impact

• This filing primarily impacts how The Vanguard Group's beneficial ownership is reported to the SEC, clarifying that the parent entity no longer directly holds or is deemed to hold shares in Altimmune Inc. but its subsidiaries may.
• It does not directly impact Altimmune Inc.'s shareholders, employees, customers, suppliers, or creditors, as it is an administrative change by an institutional investor.

Key Dates

Keywords

Altimmune Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Institutional Ownership, Realignment